Healthy Clinical Trial
— AFOCUFFOfficial title:
Comparative Effect of Carbon Fiber Orthosis Cuff Design on Preference, Comfort, and Mechanics
NCT number | NCT05456295 |
Other study ID # | 202202450 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 17, 2023 |
Est. completion date | September 2026 |
Carbon fiber custom dynamic orthoses (CDOs) consist of a proximal cuff that wraps around the leg just below the knee, a posterior carbon fiber strut that stores and returns energy during gait, and a carbon fiber foot plate that supports the foot and allows bending of the posterior strut. The proximal cuff is a primary interface between the patient and the CDO and may influence comfort, preference, limb mechanics and loading, and effective stiffness of the CDO. The important role of the proximal cuff has not been examined. The purpose of this study is to determine the effects of CDO proximal cuff design on patient reported outcomes, limb mechanics and loading, and CDO mechanical characteristics.
Status | Recruiting |
Enrollment | 34 |
Est. completion date | September 2026 |
Est. primary completion date | September 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | PARTICIPANTS WITH PTOA: Inclusion Criteria: 1. Ages 18-50. 2. Diagnosis of unilateral ankle PTOA. 3. Ability to walk 50 feet at a slow to moderate pace. 4. Ability to walk without a cane or crutch. 5. Ability to read and write in English and provide written informed consent. Exclusion Criteria: 1. Diagnosis with a moderate or severe brain injury. 2. Diagnosis with a physical or psychological condition that would preclude functional testing (e.g. cardiac condition, clotting disorder, pulmonary condition…). 3. Ankle weakness as a result of spinal cord injury or nervous system pathology. 4. Nerve, muscle, bone, or other condition limiting function in the contralateral extremity. 5. Rheumatoid or inflammatory arthritis. 6. Necrosis of any bones in the foot or ankle. 7. Pain of 8/10 or greater during walking. 8. Surgery on study limb anticipated in the next 6 months. 9. Uncorrected visual or hearing impairments. 10. Require use of a stabilizing device (i.e. Ankle Foot Orthosis or Knee Orthosis…) to perform daily activities. 11. Pregnancy 12. Body mass index greater than 40. HEALTHY ABLE-BODIED PARTICIPANTS: Inclusion Criteria: 1. Ages 18-50. 2. Without current complaint of lower extremity pain, spine pain, open wounds or active infection. 3. Ability to hop without pain. 4. Ability to perform a full squat without pain. 5. Ability to read and write in English and provide written informed consent. Exclusion Criteria: 1. Diagnosis with a moderate or severe brain injury. 2. Diagnosis with a physical or psychological condition that would preclude functional testing (e.g. cardiac condition, clotting disorder, pulmonary condition). 3. Medical conditions or injuries that have limited participation in work or exercise in the last 6 months. 4. Medical conditions of injuries limiting function for greater than 6 weeks. 5. Uncorrected visual or hearing impairments. 6. Use of an assistive device. 7. Pregnancy 8. Body mass index greater than 35. |
Country | Name | City | State |
---|---|---|---|
United States | University of Iowa | Iowa City | Iowa |
Lead Sponsor | Collaborator |
---|---|
University of Iowa | Bio-Mechanical Composites |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Center of Pressure Velocity Timing | Timing of peak center of pressure velocity (percent stance) during gait. | Baseline | |
Other | Center of Pressure Velocity Magnitude | Magnitude of peak center of pressure velocity (m/s) during gait. | Baseline | |
Other | Tibialis Anterior Muscle Activity | Electromyography (EMG, % Maximum) of the tibialis anterior during gait. | Baseline | |
Other | Peroneus Longus Muscle Activity | Electromyography (EMG, % Maximum) of the peroneus longus during gait. | Baseline | |
Other | Soleus Muscle Activity | Electromyography (EMG, % Maximum) of the soleus during gait. | Baseline | |
Other | Medial Gastrocnemius Muscle Activity | Electromyography (EMG, % Maximum) of the medial gastrocnemius during gait. | Baseline | |
Other | Semi-Structured Interview | Semi-structured interviews will also be used to fully capture the patients' perspectives, experience, and opinions associated with the device options they experienced as part of the study. | Baseline | |
Primary | Peak Plantar Force (total foot) | Force data (N) collected from the total foot (100% of sensor), measured between the foot and orthosis during gait. | Baseline | |
Primary | Plantar Force Impulse (total foot) | Plantar force impulse (Ns) across the total foot (100% of sensor) will be calculated using the integral of the force over the stance phase as participants walk in each study condition. | Baseline | |
Primary | Peak Plantar Force (forefoot) | Force data (N) collected from the total foot (distal 40% of sensor), measured between the foot and orthosis during gait. | Baseline | |
Primary | Plantar Force Impulse (forefoot) | Plantar force impulse (Ns) across the total foot (distal 40% of sensor) will be calculated using the integral of the force over the stance phase as participants walk in each study condition. | Baseline | |
Primary | Peak Plantar Force (midfoot) | Force data (N) collected from the total foot (middle 30% of sensor), measured between the foot and orthosis during gait. | Baseline | |
Primary | Plantar Force Impulse (midfoot) | Plantar force impulse (Ns) across the total foot (middle 30% of sensor) will be calculated using the integral of the force over the stance phase as participants walk in each study condition. | Baseline | |
Primary | Peak Plantar Force (hindfoot) | Force data (N) collected from the total foot (proximal 30% of sensor), measured between the foot and orthosis during gait. | Baseline | |
Primary | Plantar Force Impulse (hindfoot) | Plantar force impulse (Ns) across the total foot (proximal 30% of sensor) will be calculated using the integral of the force over the stance phase as participants walk in each study condition. | Baseline | |
Primary | Numerical Pain Rating Scale | Pain will be assessed using a standard 11-point numerical pain rating scale, in which 0 = no pain and 10 = worst pain imaginable. | Baseline | |
Primary | PROMIS Patient Reported Outcomes for Physical Function | The Patient Reported Outcome Information System (PROMIS) physical function Computer Adaptive Test (CAT) is a computerized assessment measuring physical function. It is scored using a T-score in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. In a given PROMIS domain, a T-score above 50 represents more of the measured variable than the population average. | Baseline | |
Primary | PROMIS Patient Reported Outcomes for Pain Interference | The Patient Reported Outcome Information System (PROMIS) pain interference Computer Adaptive Test (CAT) is a computerized assessment measuring pain interference. It is scored using a T-score in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. In a given PROMIS domain, a T-score above 50 represents more of the measured variable than the population average. | Baseline | |
Primary | Participant Device Preference | The participant will rank order their preference for their standard of care device (if applicable), NoCDO, CUFF-A, CUFF-B, CUFF-C, CUFF-D on a questionnaire. | Baseline | |
Secondary | Ankle Range of Motion | Peak ankle dorsiflexion (degrees) during gait. | Baseline | |
Secondary | Peak Ankle Moment | Peak ankle moment (Nm/kg) during gait. | Baseline | |
Secondary | Peak Ankle Power | Peak ankle power (W/kg) during gait. | Baseline | |
Secondary | Modified Socket Comfort Score (Comfort) | Comfort scores range from 0 = most uncomfortable to 10 = most comfortable. | Baseline | |
Secondary | Modified Socket Comfort Score (Smoothness) | Comfort scores range from 0 = least smooth to 10 = most smooth. | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |